Oxaliplatine

Oxaliplatin, the active ingredient in Oxaliplatine, is a platinum-based antineoplastic agent presented as a strength/form for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapy that acts on the DNA replication pathway of cancer cells.

- Colorectal cancer: improves survival and reduces tumour burden in metastatic and adjuvant settings. - Gastric cancer: used in combination regimens to enhance response rates. - Pancreatic cancer: contributes to disease control when combined with other agents. - Ovarian cancer: part of multi‑drug protocols for advanced disease. - Small‑cell lung cancer: employed in salvage therapy protocols. - Esophageal cancer: added to chemoradiation regimens for locally advanced disease.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: watery stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count, increasing bleed risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention. - Acute pulmonary toxicity: breathlessness or infiltrates on imaging. - Hemolytic‑uremic syndrome: rare renal and hematologic complication. - Severe neutropenia: marked drop in neutrophils leading to infection risk. - Cardiotoxicity: arrhythmias or myocardial injury in susceptible patients. - Secondary malignancies: potential long‑term risk of therapy‑related cancers.

When handling Oxaliplatin, clinicians should observe specific safety measures and patient monitoring guidelines.

- Renal function: assess creatinine clearance before and during therapy. - Hepatic function: monitor liver enzymes and bilirubin regularly. - Neuropathy risk: evaluate baseline sensory function and adjust dose if neuropathy develops. - Hematologic monitoring: perform complete blood counts prior to each cycle. - Pregnancy and lactation: avoid use; discuss risks with reproductive‑health specialists. - Storage: Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin can interact with several drug classes, affecting efficacy or toxicity.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of renal injury. - Anticoagulants (warfarin, direct oral anticoagulants): heighten bleeding potential. - Live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - CYP450 inducers (rifampicin, carbamazepine): may alter plasma levels of concomitant drugs. - Antiemetics (5‑HT3 antagonists): adjust dosing to manage nausea. - NSAIDs: monitor for additive platelet dysfunction.